ENTRADA THERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
ENTRADA THERAPEUTICS, INC. (TRDA) reported Basic Shares Outstanding (Weighted Average) of 42.22 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 42.22M shares, a 2.14% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 41.84M shares, a 1.86% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 41.61M shares, a 1.81% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 41.46M shares, a 2.05% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 41.37M shares, a 10.90% increase from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 37.31M shares, a 12.88% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 33.05M shares, a 5.61% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 31.29M shares, a 399.27% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 42.22M shares 10-Q · filed 2026-08-05 | 42.03M shares 10-Q · filed 2026-08-05 | 41.89M shares derived: average of 3 quarters · filed 2026-08-05 | 41.78M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 41.84M shares 10-Q · filed 2026-05-07 | 41.72M shares derived: average of 2 quarters · filed 2026-05-07 | 41.64M shares derived: average of 3 quarters · filed 2026-05-07 | 41.56M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 41.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 41.53M shares derived: average of 2 quarters · filed 2026-02-26 | 41.47M shares derived: average of 3 quarters · filed 2026-08-05 | 41.37M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 41.46M shares 10-Q · filed 2025-11-06 | 41.40M shares derived: average of 2 quarters · filed 2026-08-05 | 41.29M shares 10-Q · filed 2025-11-06 | 41.19M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 41.34M shares 10-Q · filed 2026-08-05 | 41.21M shares 10-Q · filed 2026-08-05 | 41.09M shares derived: average of 3 quarters · filed 2026-08-05 | 40.98M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 41.07M shares 10-Q · filed 2026-05-07 | 40.97M shares derived: average of 2 quarters · filed 2026-05-07 | 40.86M shares derived: average of 3 quarters · filed 2026-05-07 | 39.19M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 40.87M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 40.75M shares derived: average of 2 quarters · filed 2026-02-26 | 38.56M shares derived: average of 3 quarters · filed 2026-02-26 | 37.31M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 40.63M shares 10-Q · filed 2025-11-06 | 37.41M shares derived: average of 2 quarters · filed 2025-11-06 | 36.12M shares 10-Q · filed 2025-11-06 | 35.42M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 34.18M shares 10-Q · filed 2025-08-06 | 33.84M shares 10-Q · filed 2025-08-06 | 33.68M shares derived: average of 3 quarters · filed 2025-08-06 | 33.58M shares derived: average of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | 33.50M shares 10-Q · filed 2025-05-08 | 33.43M shares derived: average of 2 quarters · filed 2025-05-08 | 33.38M shares derived: average of 3 quarters · filed 2025-05-08 | 33.33M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 33.37M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 33.33M shares derived: average of 2 quarters · filed 2025-02-27 | 33.27M shares derived: average of 3 quarters · filed 2025-02-27 | 33.05M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 33.28M shares 10-Q · filed 2024-11-05 | 33.22M shares derived: average of 2 quarters · filed 2024-11-05 | 32.94M shares 10-Q · filed 2024-11-05 | 32.54M shares derived: average of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | 33.16M shares 10-Q · filed 2024-08-13 | 32.77M shares 10-Q · filed 2024-08-13 | 32.30M shares derived: average of 3 quarters · filed 2024-08-13 | 32.05M shares derived: average of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | 32.37M shares 10-Q · filed 2024-05-07 | 31.86M shares derived: average of 2 quarters · filed 2024-05-07 | 31.67M shares derived: average of 3 quarters · filed 2024-05-07 | 31.58M shares derived: average of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 31.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 31.33M shares derived: average of 2 quarters · filed 2024-03-13 | 31.31M shares derived: average of 3 quarters · filed 2024-03-13 | 31.29M shares 10-K · filed 2024-03-13 |
| 2022-09-30 | 31.30M shares 10-Q · filed 2023-11-07 | 31.29M shares derived: average of 2 quarters · filed 2023-11-07 | 31.27M shares 10-Q · filed 2023-11-07 | 28.71M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 31.28M shares 10-Q · filed 2023-08-08 | 31.26M shares 10-Q · filed 2023-08-08 | 27.85M shares derived: average of 3 quarters · filed 2023-08-08 | 21.25M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 31.25M shares 10-Q · filed 2023-05-10 | 26.13M shares derived: average of 2 quarters · filed 2023-05-10 | 17.91M shares derived: average of 3 quarters · filed 2023-05-10 | 13.76M shares derived: average of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | 21.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 11.24M shares derived: average of 2 quarters · filed 2023-03-06 | 7.93M shares derived: average of 3 quarters · filed 2023-03-06 | 6.27M shares 10-K · filed 2023-03-06 |
| 2021-09-30 | 1.48M shares 10-Q · filed 2022-11-07 | 1.39M shares derived: average of 2 quarters · filed 2022-11-07 | 1.35M shares 10-Q · filed 2022-11-07 | 1.31M shares derived: average of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | 1.31M shares 10-Q · filed 2022-08-11 | 1.29M shares 10-Q · filed 2022-08-11 | 1.25M shares derived: average of 3 quarters · filed 2022-08-11 | 1.22M shares derived: average of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | 1.26M shares 10-Q · filed 2022-05-12 | 1.22M shares derived: average of 2 quarters · filed 2022-05-12 | 1.19M shares derived: average of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | 1.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 1.16M shares derived: average of 2 quarters · filed 2022-03-15 | 1.11M shares 10-K · filed 2022-03-15 | |
| 2020-09-30 | 1.14M shares 10-Q · filed 2021-12-09 | 1.08M shares 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |